Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17025936 | 0.89 | PLCG1 (0.40) | PLCG1SSTR4P2RY1SLC22A12NFE2L2 | |
| SCHEMBL17138019 | 0.81 | TRPV4 (0.38) | PLCG1SSTR4P2RY1SLC22A12NFE2L2 | |
| SCHEMBL5709016 | 0.78 | SLC22A12 (0.47) | SSTR4P2RY1SLC22A12NFE2L2SSTR1 | |
| SCHEMBL16678279 | 0.77 | PLCG1 (0.40) | PLCG1SSTR4P2RY1SLC22A12SSTR1 | |
| SCHEMBL4947195 | 0.74 | SSTR4 (0.44) | SSTR4P2RY1SLC22A12NFE2L2SSTR1 | |
| SCHEMBL17138021 | 0.73 | P2RY1 (0.38) | PLCG1SSTR4P2RY1SLC22A12NFE2L2 | |
| SCHEMBL5709212 | 0.72 | TRPV1 (0.43) | SSTR4P2RY1SLC22A12SSTR1TRPV1 | |
| SCHEMBL29100772 | 0.71 | P2RY1 (0.44) | PLCG1P2RY1P2RY14 | |
| SCHEMBL2635568 | 0.71 | KIF11 (0.42) | SSTR4P2RY1SLC22A12NFE2L2SSTR1 | |
| SCHEMBL1597855 | 0.71 | NOS3 (0.42) | SSTR4SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580463-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-9409943-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150376233-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-31 | — | — | US | disclosed |
| US-20150239930-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239930-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, GOT1 | PLCG1 2933/4885SSTR4 4816/4885P2RY1 4081/4885 |
| US-20150376233-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, GOT1 | PLCG1 2933/4885SSTR4 4816/4885P2RY1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.